Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06669572 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 1,280 words
    • Site contact updated
    v6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 13, 2026 to Jul 11, 2025
    • Study site revised
    v5
  3. Start date: Jan 13, 2025 to Jan 13, 2026
    • Secondary endpoints revised (4)
    v4
  4. Secondary endpoints: details revised at 1 of 4 entriesv3
  5. Secondary endpoints: details revised at 1 of 4 entriesv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to gather information on the safety and effectiveness of lenvatinib combined with pembrolizumab in anal/rectal cancer that has spread to other parts of the body and will not respond to standard care.
Trial Details
NCT Number NCT06669572
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 Carcinoma, Squamous Cell, Anorectal Cancer
Related terms Carcinoma, Squamous Cell
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov